This is a correction to: Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janice M Walshe, Gamini S Soori, Shaker R Dakhil, James L Wade, Edward C McCarron, Sandra M Swain, Norman Wolmark, Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer, JNCI: Journal of the National Cancer Institute, 2023, djad078, https://doi.org/10.1093/jnci/djad078
In the originally published version of this manuscript, Reference 19 was erroneously cited in the following sentence in the ‘Discussion’ section:
‘Because the relationship between serum estrogen levels and bone mineral density is well-established (19), it is important to further explore if serum estrogen levels in postmenopausal women can be used as surrogate markers of the effect of EET.’
The reference that should have been cited in this sentence is as follows:
‘Rapuri PB, Gallagher JC, Haynatzki G. Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. J Clin Endocrinol Metab. 2004 Oct;89(10):4954-62. doi: 10.1210/jc.2004-0434. Erratum in: J Clin Endocrinol Metab. 2005 Mar;90(3):1711. https://pubmed.ncbi.nlm.nih.gov/15472191/.
This reference has now been added to the reference list as Reference 20 and the affected sentence has been corrected accordingly.
The following reference has been added as reference 21:
Amir E, Seruga B, Niraula S, et al.: Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis. J Natl Cancer Inst 103:1299-1309, 2011. https://pubmed.ncbi.nlm.nih.gov/21743022/.
Subsequent affected references and their in-text citations have also been corrected.